Drug Database
BE

bepotastine besilate (Talion OD)

✓ Approved

Mitsubishi Tanabe Pharma Corporation · HRH1 · 小分子

什么是 bepotastine besilate?

bepotastine besilate 是一种小分子,由Mitsubishi Tanabe Pharma Corporation研发。该药已获批,用于治疗相关适应症,给药途径:Oral (PO)。

药物档案

商品名Talion OD
公司Mitsubishi Tanabe Pharma Corporation
药物类别小分子
分子靶点HRH1
给药途径Oral (PO)
状态Approved

作用机制

分子靶点

bepotastine besilate 作用于 1 个分子靶点:

HRH1histamine receptor H1 (HH1R, H1R)
需要更深入的分析?Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

bepotastine besilate 针对 4 个适应症,涉及 3 个治疗领域。

治疗领域疾病/病症分期
Immune system disordersHypersensitivity✓ Approved
Skin and subcutaneous tissue disordersPruritus✓ Approved
Respiratory, thoracic and mediastinal disordersRhinitis allergic✓ Approved
Skin and subcutaneous tissue disordersUrticaria✓ Approved

相关研究文献

PubMedIEEE transactions on image processing : a publication of the IEEE Signal Processing Society2026-11-17

Fast and Compressed ADA-UNet: Refractive-Index Reconstruction with Latent-Domain Low-Rank Compression.

Chiang Po-Jui PJ, Lin Yu-Da YD, Yang Cheng-Hong CH

Optical diffraction tomography (ODT) provides label-free three-dimensional refractive-index (RI) maps, but conventional reconstructions are highly sensitive to speckle noise and severely under-sampled illumination angles. We propose ADA-UNet, a compact two-stage framework in which (i) a modality-specific autoencoder learns a compact representation of stitched diffraction inputs, and (ii) a latent-domain ResUNet maps these interferometric latent codes to RI latent codes for non-iterative reconstruction. For compactness, the interferometry-to-RI mapping is expressed in Dirac form, but the network itself is implemented entirely with standard convolutional operators on GPU hardware. To reduce computational cost without changing the reconstruction objective, low-rank factorization is applied specifically to the ADA-aligned latent mapper. The resulting compressed model, ADA-UNetc, reduces the parameter count from 12.5M to 6.0M (a 52% reduction) while maintaining nearly unchanged reconstruction quality, with SSIM changing from 0.943 to 0.940 and NRMSE from 0.051 to 0.052. Across all evaluated ODT, cross-modal image-synthesis, and adaptation baselines, the proposed model achieves the best overall fidelity and a measured per-volume inference time of 187 s, compared with 221-840 s for the baselines. Experiments on synthetic and real 2-D/3-D data further demonstrate robustness under evaluation-time noise perturbations and sparse-angle acquisition, highlighting the potential of ADA-UNet for efficient and reliable quantitative phase imaging.

PMID 43043740
阅读全文 →
PubMedFrontiers in pharmacology2026-11-17

Comparative efficacy and safety of topical olopatadine formulations for allergic conjunctivitis: a systematic review and network meta-analysis.

Li Caiju C, Gao Yuying Y, Wei Lijuan L

Allergic conjunctivitis (AC) affects 15%-40% of the global population. Traditional network meta-analyses often group different formulations of olopatadine into a single node, obscuring concentration-dependent variations. This network meta-analysis evaluated the relative efficacy and safety of distinct olopatadine concentrations (0.1%, 0.2%, 0.77%) against other topical anti-allergic or anti-inflammatory agents. Registered in PROSPERO (CRD420261375330), this study systematically searched major databases up to 1 May 2026, for randomized controlled trials (RCTs) on adults with AC. Interventions evaluated olopatadine formulations (0.1% BID, 0.2% QD, 0.77% QD) as independent nodes alongside 0.05% epinastine, 0.025% ketotifen, 0.25% alcaftadine, 1.5% bepotastine, 0.2% loteprednol etabonate, or placebo. Frequentist random-effects network meta-analyses were performed. Nineteen randomized controlled trials (RCTs) encompassing 2,745 patients (5,141 eyes) were analyzed. For ocular itching (18 RCTs), 0.77% olopatadine demonstrated superior efficacy among dual-acting agents (SUCRA = 80.7%), significantly outperforming epinastine and ketotifen. For conjunctival hyperemia (17 RCTs), 0.25% alcaftadine demonstrated the highest likelihood of efficacy (SUCRA = 66.5%), whereas among olopatadine formulations, only 0.2% significantly outperformed placebo (SUCRA = 47.4%). Subgroup analyses showed that 0.77% olopatadine and 0.25% alcaftadine were particularly effective against acute itching in conjunctival allergen challenge models. Safety assessments across 11 RCTs yielded wide confidence intervals due to data sparsity, precluding definitive tolerability rankings. Although trial data predominantly reported mild adverse events, external evidence highlights key long-term safety concerns, notably intraocular pressure elevation associated with extended topical corticosteroid therapy such as 0.2% loteprednol etabonate. Topical dual-acting agents demonstrate outcome-specific efficacy variations in allergic conjunctivitis management. Olopatadine 0.77% excels in pruritus control, whereas alcaftadine 0.25% provides the highest likelihood of hyperemia resolution. Clinical management should adopt a personalized step-ladder approach: utilizing potent once-daily dual-acting agents (0.77% olopatadine or 0.25% alcaftadine) as first-line therapy for acute or seasonal exposure. Short-term topical corticosteroids (such as 0.2% loteprednol etabonate) should be strictly reserved for severe natural exposure non-responsive to dual-acting agents, with mandatory intraocular pressure monitoring, before transitioning back to dual-acting maintenance.

PMID 43042078
阅读全文 →
PubMedCarbohydrate polymers2026-11-16

Boron-complexed oxidized dextran/carboxymethyl chitosan hydrogel loaded with paeoniflorin alleviates UC via TLR4-NF-κB pathway regulation and intestinal mucosal barrier restoration.

Li Shengyu S, Pan Yuting Y, Wang Gang G, Fang Jintao J et al.

Ulcerative colitis (UC) is a chronic relapsing inflammatory bowel disease characterized by large-intestinal mucosal ulceration and persistent inflammation, which manifests as bloody diarrhea and abdominal pain and may elevate colorectal cancer risk. Polysaccharide-based hydrogels are attractive candidates for local rectal therapy of UC owing to favorable biocompatibility; however, their therapeutic performance is compromised by short lesion residence time caused by continuous intestinal peristalsis. Herein, we fabricated a muco-adaptive multifunctional hydrogel (B-ODT/CM@PF) constructed via dual-dynamic cross-linking of boronate-diol ester bonds and Schiff-base imine bonds for local treatment of UC. The carboxymethyl chitosan component contributes to rapid local hemostasis and epithelial barrier repair, whereas boron-complexed oxidized dextran confers broad-spectrum bactericidal capacity by disrupting bacterial membrane integrity. Benefiting from boronate-diol interactions, paeoniflorin (PF) is anchored within hydrogel networks to realize inflammation-triggered sustained release. The released PF targets the TLR4-NF-κB signaling axis to drive macrophage M2 polarization and mitigate excessive intestinal inflammatory responses. Moreover, B-ODT/CM@PF rescues the integrity of the intestinal mucosal barrier by inhibiting MLCK activation and preserving tight-junction proteins expression, further ameliorating colitis manifestations. Collectively, this dual-crosslinked bioadhesive hydrogel achieves synergistic functions including mucosal adhesion, hemostasis, antibacterial activity, immunomodulation and barrier reconstruction, providing a promising strategy for local treatment of UC.

PMID 43039541
阅读全文 →
PubMedAllergy and asthma proceedings2026-11-14

Real-world experience with oral on-demand treatment sebetralstat for hereditary angioedema in a retrospective case series.

Lochbaum Robin R, Mohrle Raphael R, Hoffmann Thomas K TK, Greve Jens J et al.

Patients with hereditary angioedema (HAE) have unpredictable swelling attacks that can be painful and lifethreatening. Despite guidelines that recommend early on-demand treatment (ODT) for every attack, real-world adherenceremains suboptimal, partly due to treatment barriers with parenteral treatments, the only options available until 2025. The objective was to report the real-world experience with sebetralstat, the first approved oral ODT for all HAEtypes. This single-center retrospective analysis (May 2025 to February 2026) describes patient-reported reasons for switching to oral sebetralstat in 12 patients with HAE, 3 in a compassionate use program (CUP), and 9 after market authorization (October 2025), complemented by clinical outcomes and disease control in the 3 patients in CUP. The cohort included nine patients with HAE due to C1-inhibitor deficiency and three with normal C1-inhibitor HAE. Eight patients previously used subcutaneous icatibant, three used intravenous C1-inhibitor concentrate, and one used both. Reasons for switching were administration-related treatment barriers (8/12 [66.7%]), improved lifestyle compatibility(6/12 [50.0%]), and enhanced treatment autonomy (5/12 [41.7%]). The three patients in CUP initiated treatment ~20 minutes after symptom onset in 13 of 14 attacks (nocturnal facial attack: time unknown). Symptom relief occurred after ~20-30 minutes. Thirteen of 14 attacks resolved completely between 30 minutes and 4 hours after symptom relief (facial attack: 6 hours). All attacks were treated with a single 300-mg dose. No adverse events or rebound attacks were documented. Angioedema Control Test scores decreased but remained greater than or equal to 10. This initial real-world experience shows that 8 of 12 patients switched to sebetralstat because of administration-related treatment barriers, interpreted as a greater willingness to initiate oral treatment. The three patients in CUP initiatedtreatment with oral sebetralstat early for all but one attack. These preliminary findings suggest that oral administrationmay reduce barriers associated with parenteral ODT.

PMID 43025858
阅读全文 →
PubMedJA clinical reports2026-11-13

More vasopressors were required during anesthesia maintenance with sevoflurane than remimazolam in a high-risk patient: a case report.

Arai Yusuke Y, Tsukamoto Miku M, Masui Kenichi K

Remimazolam besilate is known to cause less hypotension than other anesthetics. We experienced an anesthetic switch from remimazolam to sevoflurane in a high-risk patient, allowing us to compare the intra-individual hemodynamic effects of the two anesthetics. A 57-year-old woman with multiple cardiovascular complications underwent a lower-limb amputation. We selected remimazolam anesthesia with peripheral nerve blocks to minimize the risk of intraoperative hypotension. During the closure of the surgical site after deflating the tourniquet, we switched anesthetics from remimazolam to sevoflurane because the attending anesthesiologist had to leave for other duties. Then, repeated doses of phenylephrine were required throughout the remainder of the surgery, despite comparable surgical and other anesthetic conditions before and after the switch. After discontinuation of sevoflurane and remifentanil, noradrenaline was no longer required. This case report has shown that additional vasopressors were required during anesthesia maintenance with sevoflurane after switching from remimazolam.

PMID 43020906
阅读全文 →
PubMedESC heart failure2026-11-12

Diuretic Response in Acute Heart Failure: Prediction vs Direct Measurement.

Ivey-Miranda Juan J, Cox Zachary Z, Udelson James E JE, Nunez Julio J et al.

Limited data are available informing the variability and ability to predict diuretic response (DR) longitudinally during decongestion in acute heart failure (AHF). The FASTR pilot trial compared the Reprieve System (n=52) to optimal diuretic therapy control (ODT) (n=44). The ability to longitudinally predict DR, quantified as urine output over the 72-hour intervention, was evaluated in the overall population using baseline characteristics. In the Reprieve arm, directly measured DR during the initial dose finding algorithm was also used to predict longitudinal DR. Baseline characteristics predicted only 24.7% (p<0.001) of the variance in DR over the course of IV diuretic therapy. As the duration of diuretic therapy increased, DR prediction worsened with no relationship to DR after 18 hours (p≥0.097). Directly measured DR strongly predicted subsequent urine output early (e.g., predicting 84.5% in the variance of the subsequent hour DR, p<0.001). However, this also decreased over time with modest correlation with DR at 24 hours (variance 12.7%; p=0.008) and no correlation after 48 hours (p=0.79). In the Reprieve group, serial DR measurement and diuretic titration occurred in 89% of patients eligible for further diuretic titration resulting in stable therapeutic DR over the study period despite the changes in DR over time. Accurately predicting longitudinal DR using baseline characteristics or a single direct measurement of DR is challenging as DR changes rapidly during decongestion. Due to the dynamic nature of DR over therapy, serial assessment and diuretic titration is required to longitudinally achieve therapeutic DR in most AHF patients.

PMID 43017786
阅读全文 →

注册免费账户还可查看另外 1397 篇文献

免费注册查看全部文献 →

了解更多bepotastine besilate